G. Gilliland

发表

Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction.

S. Perrin, H. Bunn, G. Gilliland, 1990, Proceedings of the National Academy of Sciences of the United States of America.

8 – COMPETITIVE PCR FOR QUANTITATION OF mRNA

S. Perrin, H. Bunn, G. Gilliland, 1990 .

expert panel primary myelofibrosis: recommendations from an ad hoc international diagnostic criteria for polycythemia vera, essential thrombocythemia, and Proposals and rationale for revision of the World Health Organization

T. Barbui, D. Bloomfield, S. Verstovsek, 2013 .

JAK2 mutations in myeloproliferative disorders.

A. Tefferi, T. Lasho, G. Gilliland, 2005, The New England journal of medicine.

-secretase inhibitors γ Notch1 mutations and are sensitive to induced T-cell lymphoblastic lymphoma/leukemias harbor - K-RasG12D

S. Fröhling, C. Scholl, D. Leeman, 2013 .

Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.

O. Bernard, P. Dessen, O. Bawa, 2018, Blood advances.

High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.

Shaun Parsons, E. Guinan, P. Mauch, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

colony-stimulating factor or interleukin-3 oncogenes does not require granulocyte-macrophage Induction of myeloproliferative disease in mice by tyrosine kinase fusion

M. Tomasson, G. Dranoff, R. A. Etten, 2013 .

Somatic mutations of the aml-1 gene are frequent in acute myeloid leukemia with fab mo morphology

J. Downing, F. Behm, L. Shih, 2000 .

A new data effort to inform career choices in biomedicine

Freeman A. Hrabowski, M. Pollack, R. Blank, 2017, Science.

FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.

P. Marynen, J. Cools, G. Gilliland, 2004, The hematology journal : the official journal of the European Haematology Association.

Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease.

B. Blazar, R. Gingrich, G. Gilliland, 1990, Blood.

JAK2 V617F 10 Years Later: Dr. Dameshek's Prophecy Fulfilled

R. Levine, G. Gilliland, R. Levine, 2015 .

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

C. Moskaluk, J. Aster, B. Bernstein, 2014, Cancer discovery.

Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma Discovery of Biomarkers Predictive of GSI Response in

C. Moskaluk, J. Aster, B. Bernstein, 2014 .

Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.

A. Tefferi, G. Gilliland, 2006, Best practice & research. Clinical haematology.

Site-specific mutagenesis using asymmetric polymerase chain reaction and a single mutant primer.

S. Perrin, G. Gilliland, S Perrin, 1990, Nucleic acids research.

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.

K. Akashi, H. Iwasaki, K. Takenaka, 2009, Blood.

Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1‐ETO

W. Hiddemann, C. Buske, T. Haferlach, 2006, British journal of haematology.

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

C. Paweletz, P. Majumder, K. Kunii, 2012, Translational oncology.

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

H. Hirsch, M. Ayers, A. Loboda, 2014, PloS one.

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

Arghya Ray, Jan Cools, Leigh Zawel, 2007, Molecular Cancer Therapeutics.

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Pascal Furet, Guido Bold, Arghya Ray, 2008, Blood.

myeloproliferative phenotype Loss of Runx1 perturbs adult hematopoiesis and is associated with a

J. Kutok, K. Akashi, N. Speck, 2013 .

Multiple clones with (3;21) translocation in a case of Ph-positive chronic myelogenous leukemia during relapse after allogeneic bone marrow transplantation.

D. Rosenthal, G. Gilliland, R. Tantravahi, 1990, Cancer genetics and cytogenetics.

Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemia

D. Neuberg, D. Tenen, T. Pabst, 2006, British Journal of Cancer.

Keeping bass alive: a guidebook for anglers and tournament or-ganizers

G. Gilliland, Helmuth Schramm, 2002 .

Myelodysplastic syndrome

G. Gilliland, R. Legare, 1995, Current opinion in hematology.

Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML)

T. Rebbeck, J. Maris, M. Poncz, 1998, Blood.

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

R. Levine, B. Druker, M. Heinrich, 2009, Blood.

Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.

Samuel J. Taylor, D. Gilliland, W. Langdon, 2015, Experimental hematology.

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

C. Moskaluk, J. Aster, B. Bernstein, 2014, Cancer discovery.